227 related articles for article (PubMed ID: 26502337)
1. Recurrent inactivating RASA2 mutations in melanoma.
Arafeh R; Qutob N; Emmanuel R; Keren-Paz A; Madore J; Elkahloun A; Wilmott JS; Gartner JJ; Di Pizio A; Winograd-Katz S; Sindiri S; Rotkopf R; Dutton-Regester K; Johansson P; Pritchard AL; Waddell N; Hill VK; Lin JC; Hevroni Y; Rosenberg SA; Khan J; Ben-Dor S; Niv MY; Ulitsky I; Mann GJ; Scolyer RA; Hayward NK; Samuels Y
Nat Genet; 2015 Dec; 47(12):1408-10. PubMed ID: 26502337
[TBL] [Abstract][Full Text] [Related]
2. Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system.
van de Nes J; Gessi M; Sucker A; Möller I; Stiller M; Horn S; Scholz SL; Pischler C; Stadtler N; Schilling B; Zimmer L; Hillen U; Scolyer RA; Buckland ME; Lauriola L; Pietsch T; Waha A; Schadendorf D; Murali R; Griewank KG
J Neurooncol; 2016 May; 127(3):435-44. PubMed ID: 26744134
[TBL] [Abstract][Full Text] [Related]
3. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
4. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.
Krauthammer M; Kong Y; Bacchiocchi A; Evans P; Pornputtapong N; Wu C; McCusker JP; Ma S; Cheng E; Straub R; Serin M; Bosenberg M; Ariyan S; Narayan D; Sznol M; Kluger HM; Mane S; Schlessinger J; Lifton RP; Halaban R
Nat Genet; 2015 Sep; 47(9):996-1002. PubMed ID: 26214590
[TBL] [Abstract][Full Text] [Related]
5. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.
Hintzsche JD; Gorden NT; Amato CM; Kim J; Wuensch KE; Robinson SE; Applegate AJ; Couts KL; Medina TM; Wells KR; Wisell JA; McCarter MD; Box NF; Shellman YG; Gonzalez RC; Lewis KD; Tentler JJ; Tan AC; Robinson WA
Melanoma Res; 2017 Jun; 27(3):189-199. PubMed ID: 28296713
[TBL] [Abstract][Full Text] [Related]
6. Analysis of SDHD promoter mutations in various types of melanoma.
Scholz SL; Horn S; Murali R; Möller I; Sucker A; Sondermann W; Stiller M; Schilling B; Livingstone E; Zimmer L; Reis H; Metz CH; Zeschnigk M; Paschen A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Oncotarget; 2015 Sep; 6(28):25868-82. PubMed ID: 26327518
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation.
Sung H; Kanchi KL; Wang X; Hill KS; Messina JL; Lee JH; Kim Y; Dees ND; Ding L; Teer JK; Yang S; Sarnaik AA; Sondak VK; Mulé JJ; Wilson RK; Weber JS; Kim M
Oncotarget; 2016 Apr; 7(17):23885-96. PubMed ID: 26993606
[TBL] [Abstract][Full Text] [Related]
8. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
[TBL] [Abstract][Full Text] [Related]
9. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Krauthammer M; Kong Y; Ha BH; Evans P; Bacchiocchi A; McCusker JP; Cheng E; Davis MJ; Goh G; Choi M; Ariyan S; Narayan D; Dutton-Regester K; Capatana A; Holman EC; Bosenberg M; Sznol M; Kluger HM; Brash DE; Stern DF; Materin MA; Lo RS; Mane S; Ma S; Kidd KK; Hayward NK; Lifton RP; Schlessinger J; Boggon TJ; Halaban R
Nat Genet; 2012 Sep; 44(9):1006-14. PubMed ID: 22842228
[TBL] [Abstract][Full Text] [Related]
10. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
[TBL] [Abstract][Full Text] [Related]
11. A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients.
Cursons J; Souza-Fonseca-Guimaraes F; Foroutan M; Anderson A; Hollande F; Hediyeh-Zadeh S; Behren A; Huntington ND; Davis MJ
Cancer Immunol Res; 2019 Jul; 7(7):1162-1174. PubMed ID: 31088844
[TBL] [Abstract][Full Text] [Related]
12. Recurrent co-alteration of HDGF and SETDB1 on chromosome 1q drives cutaneous melanoma progression and poor prognosis.
Fazio M; van Rooijen E; Mito JK; Modhurima R; Weiskopf E; Yang S; Zon LI
Pigment Cell Melanoma Res; 2021 May; 34(3):641-647. PubMed ID: 33064882
[TBL] [Abstract][Full Text] [Related]
13. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
14. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
Hodi FS; Corless CL; Giobbie-Hurder A; Fletcher JA; Zhu M; Marino-Enriquez A; Friedlander P; Gonzalez R; Weber JS; Gajewski TF; O'Day SJ; Kim KB; Lawrence D; Flaherty KT; Luke JJ; Collichio FA; Ernstoff MS; Heinrich MC; Beadling C; Zukotynski KA; Yap JT; Van den Abbeele AD; Demetri GD; Fisher DE
J Clin Oncol; 2013 Sep; 31(26):3182-90. PubMed ID: 23775962
[TBL] [Abstract][Full Text] [Related]
15. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4.
Johansson P; Aoude LG; Wadt K; Glasson WJ; Warrier SK; Hewitt AW; Kiilgaard JF; Heegaard S; Isaacs T; Franchina M; Ingvar C; Vermeulen T; Whitehead KJ; Schmidt CW; Palmer JM; Symmons J; Gerdes AM; Jönsson G; Hayward NK
Oncotarget; 2016 Jan; 7(4):4624-31. PubMed ID: 26683228
[TBL] [Abstract][Full Text] [Related]
16. Integrating Next-Generation Sequencing with Morphology Improves Prognostic and Biologic Classification of Spitz Neoplasms.
Quan VL; Zhang B; Zhang Y; Mohan LS; Shi K; Wagner A; Kruse L; Taxter T; Beaubier N; White K; Zou L; Gerami P
J Invest Dermatol; 2020 Aug; 140(8):1599-1608. PubMed ID: 32004563
[TBL] [Abstract][Full Text] [Related]
17. Novel mutations identified by whole-exome sequencing in acral melanoma.
Lim Y; Yoon D; Lee DY
J Am Acad Dermatol; 2020 Dec; 83(6):1792-1794. PubMed ID: 32278801
[No Abstract] [Full Text] [Related]
18. Melanomas Associated With Blue Nevi or Mimicking Cellular Blue Nevi: Clinical, Pathologic, and Molecular Study of 11 Cases Displaying a High Frequency of GNA11 Mutations, BAP1 Expression Loss, and a Predilection for the Scalp.
Costa S; Byrne M; Pissaloux D; Haddad V; Paindavoine S; Thomas L; Aubin F; Lesimple T; Grange F; Bonniaud B; Mortier L; Mateus C; Dreno B; Balme B; Vergier B; de la Fouchardiere A
Am J Surg Pathol; 2016 Mar; 40(3):368-77. PubMed ID: 26645730
[TBL] [Abstract][Full Text] [Related]
19. NF1 mutations in conjunctival melanoma.
Scholz SL; Cosgarea I; Süßkind D; Murali R; Möller I; Reis H; Leonardelli S; Schilling B; Schimming T; Hadaschik E; Franklin C; Paschen A; Sucker A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Br J Cancer; 2018 May; 118(9):1243-1247. PubMed ID: 29559732
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants.
Ticha I; Hojny J; Michalkova R; Kodet O; Krkavcova E; Hajkova N; Nemejcova K; Bartu M; Jaksa R; Dura M; Kanwal M; Martinikova AS; Macurek L; Zemankova P; Kleibl Z; Dundr P
Sci Rep; 2019 Nov; 9(1):17050. PubMed ID: 31745173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
